hotspot -WSS

hotspot

author：leisure time 2025-08-27 18:59:37 - browse：12862

An army of wooden figures under blue and pink lighting — biotech coverage from STAT — Adobe

In an abrupt change of course from plans earlier in the month, at-home test maker Cue Health is laying off all of its employees and shutting down as of Friday, May 24.

The company, which grew to prominence during the Covid-19 pandemic as the maker of one of the only molecular at-home tests for the virus, has been teetering on the edge of insolvency for months. The shutdown, first reported by the San Diego Union-Tribune, comes just over a week after the FDA warned consumers not to use Cue’s only FDA-authorized product, a Covid-19 test kit.

Cue had previously notified 49% of its workers on May 1 that they would be laid off from the company, effective July 1. But in a WARN notice filed with California state regulators on May 20, chief human resources officer Allison Blackwell said that due to the “fluid nature of this situation,” all U.S. employees who had not already received notice of termination would be receiving one. All employees will receive their last paychecks on May 24, the notice said.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： PEPFAR is under serious threat — and so is global health

explore

hotspot

focus

WSS

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

Diverse clinical trials: Why aren’t we there yet?

Friends ask where James Watson's attitudes about race came from

American woman, child freed after being kidnapped in Haiti last month

FDA panel endorses Alnylam’s heart drug — after picking it apart

Wegovy’s successful heart trial raises vital question about weight loss

Wikipedia

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

Duchenne breakthrough therapy leaves behind pioneering families

What to make of Biden’s latest efforts on cancer research

Medical records are filled with copy

Generate Biomedicines machine learning biotech raises $273M

Anesthesiologist group: stop taking Ozempic before surgery

Emergent cuts jobs, executive role in business shake

ChatGPT in medicine: STAT answers readers' burning questions

Food makers to regulators: Ultra

Activists slam private health insurers over coverage restrictions

FDA approves updated Covid vaccines

knowledge

Pig kidney works a record two months in donated body

FDA approves updated Covid vaccines

Anavex keeps shifting the goalposts in its clinical trials

Wegovy trial has doctors encouraged over new possibilities

What to know about Virgin Galactic's 1st mission taking paying customers to space

Wegovy trial has doctors encouraged over new possibilities

explore

hotspot

focus

entertainment